Skip to main content
    M

    Mineralys Therapeutics, Inc. Common Stock (MLYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.53
    -0.80 (-5.22%)

    Market Cap: $1.36B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Mineralys Therapeutics, Inc. Common Stock (MLYS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Mineralys Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$154.65M, operating cash flow was -$142.42M and free cash flow was -$142.43M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$57.33M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $170.60M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Research and development$132.01M$168.58M$70.36M$26.25M$16.31M$2.41M
    Operating income-$170.60M-$192.40M-$84.66M-$31.48M-$18.73M-$2.94M
    Net income-$154.65M-$177.81M-$71.90M-$29.80M-$19.41M-$3.43M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$34.00K$0$0$0$0
    Gross profit$0$0$0-$13.00K$0$0$0$17.00K$0$0$0N/A
    Operating income-$60.09M-$246.04M-$45.34M-$38.28M-$41.13M-$46.75M-$44.45M-$51.77M-$60.11M-$45.17M-$35.36M-$27.71M
    Net income-$57.33M-$241.07M-$39.34M-$32.23M-$36.93M-$43.27M-$42.21M-$48.95M-$56.34M-$41.01M-$31.51M-$24.39M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, the balance sheet showed $172.92M in cash and equivalents and no debt.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$661.81M$205.90M$251.64M$114.44M$11.13M$1.49M
    Current assets$661.39M$205.35M$249.10M$112.81M$11.12M$1.47M
    Cash and equivalents$172.92M$114.09M$49.30M$87.70M$10.61M$1.41M
    Total liabilities$15.11M$14.65M$10.48M$8.07M$34.05M$5.08M
    Short-term debt$0N/AN/AN/AN/A$4.50M
    Shareholder equity$646.69M$191.26M$241.15M-$52.27M-$22.93M-$3.60M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$630.12M$667.85M$652.86M$661.81M$599.95M$335.72M$354.94M$205.90M$268.25M$318.49M$347.25M$251.64M
    Total liabilities$126.35M$116.94M$14.72M$15.11M$23.52M$22.17M$13.39M$14.65M$31.32M$28.40M$19.20M$10.48M
    Cash and equivalents$101.27M$138.27M$112.78M$172.92M$217.60M$101.79M$165.01M$114.09M$97.27M$67.86M$90.42M$49.30M
    Shareholder equity$503.77M$550.92M$638.14M$646.69M$576.43M$313.55M$341.56M$191.26M$236.93M$290.10M$328.05M$241.15M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$142.42M-$166.31M-$81.17M-$29.22M-$14.56M-$2.46M
    Capital expenditures$15.00K$96.00K$0$0$0$0
    Free cash flow-$142.43M-$166.41M-$81.17M-$29.22M-$14.56M-$2.46M
    Dividends paidN/AN/AN/AN/AN/A$3.83M
    Share repurchases$391.00K$435.00K$0N/AN/AN/A
    Investing cash flow-$389.75M$114.96M-$160.47M-$21.76M-$21.76M-$21.76M
    Financing cash flow$591.00M$116.14M$203.25M$128.02M$23.81M$3.83M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$43.10M-$32.56M-$39.47M-$37.89M-$28.87M-$30.17M-$45.49M-$66.84M-$50.19M-$30.15M-$19.14M-$28.98M
    Capital expendituresN/AN/A$0$15.00K$0$0$0$0$37.00K$0$59.00K$0
    Free cash flowN/AN/A-$39.47M-$37.90M-$28.87M-$30.17M-$45.49M-$66.84M-$50.22M-$30.15M-$19.20M-$28.98M
    Last 12 quarters

    Frequently Asked Questions About MLYS

    What is Mineralys Therapeutics, Inc. Common Stock's annual revenue?

    Mineralys Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Mineralys Therapeutics, Inc. Common Stock profitable?

    No. Mineralys Therapeutics, Inc. Common Stock reported net income of -$154.65M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does MLYS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$142.42M minus capital expenditures of $15.00K produced free cash flow of -$142.43M.

    How much debt does Mineralys Therapeutics, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $172.92M.